ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.
Overview
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT04891198 by 3D Medicines (Sichuan) Co., Ltd., with 126 participants planned, started 2021-08-06 and due to reach its primary completion in 2027-08-30. Interventions recorded: Envafolimab.
Similar pages
not linked directly; found by shared links- TrialKN035 for dMMR/MSI-H Advanced Solid Tumors
Shares Envafolimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialProgrammed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
Shares Envafolimab and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.